MEDIPOST Lowers Conversion Price by 30% on 10th and 11th CBs, Expanding Potential Dilution
MEDIPOST announced a 30% downward adjustment of the conversion price for its 10th and 11th series unsecured private convertible bonds from 17,981 KRW to 12,587 KRW.
The adjustment is triggered by the reference price falling below the current conversion price six months after issuance, increasing the total convertible shares to 2,383,411 for the 10th series and 1,986,176 for the 11th series, a combined increase of 1,310,804 shares.
The lower conversion price expands potential dilution by approximately 30% compared to the original terms. While the new conversion price of 12,587 KRW remains above the current stock price of 9,470 KRW, a future price recovery could lead to higher conversion activity, pressuring existing shareholder value.
[AI Summary]The market price adjustment increased potential dilution by 1,310,804 shares, representing about 3.34% of outstanding shares. With no new capital raised, the capital allocation impact is neutral, but the lower conversion price raises the risk of future equity dilution, capping upside potential.